Breast cancer
Conditions
Interventions
TCA group:Epirubicin + cyclophosphamide + docetaxel neoadjuvant therapy
TCA program + Xihuangwan group:Epirubicin + cyclophosphamide + docetaxel + xihuangwan neoadjuvant therapy
control subjects:No special treatment
Xihuangwan group:3 days of Xihuangwan treatment during preparation for surgery
Sponsors
The Second Affiliated Hospital of Shandong First Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) female patients with triple-negative breast cancer diagnosed by puncture histology: (2) age =18 and =75 years old not receiving neoadjuvant/adjuvant chemotherapy: (3) patients with an ECOG score of =1; (4) conscious judgmental about pain able to cooperate in evaluating pain and quality of life and with normal expressive ability; (5) voluntarily signing an informed consent form; and (6) agreeing to undergo epirubicin + cyclophosphamide + docetaxel + xihuangwan neoadjuvant therapy
Exclusion criteria
Exclusion criteria: (1) Mental disorders language disorders; (2) Combined visceral metastases; (3) Combined severe cardiac pulmonary hepatic and renal dysfunction; (4) Nursing women pregnant women; (5) Cannot sign the informed consent; (6) Incomplete information to judge the efficacy of the treatment; (7) Can not cooperate with the treatment and withdraw halfway; (8) Changes in the condition need to change the treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunohistochemical detection of CRT HMGB1 HSP70/90; | — |
Secondary
| Measure | Time frame |
|---|---|
| Determination of tumor diameter by color ultrasound; | — |
Countries
China
Contacts
Public ContactXingchao Xu
The Second Affiliated Hospital of Shandong First Medical University No.366 Taishan Street Tai'an City Shandong Province China
Outcome results
None listed